Chimerix.com redirects to Jazz Pharmaceuticals—a $300M revenue biotech that just acquired Chimerix for $441M. This isn't just another domain redirect; it's a strategic pivot into oncology that reveals how mid-cap pharma companies are hunting for their next blockbuster.

"When a biotech's domain redirects to its acquirer, it's either death or evolution. Chimerix chose evolution—trading independence for Jazz's commercial muscle."

• Domain redirects to Jazz Pharmaceuticals—complete brand absorption
• 46% direct traffic indicates existing investor/clinical community awareness
• Top keywords reveal dual identity: misspelled brand (6,650) vs. drug pipeline (540)
• 19 technologies detected—enterprise stack for a clinical-stage biotech

The traffic data tells a story of a company in transition. With 3,416 monthly visits and 33% organic search, Chimerix's digital footprint was modest before acquisition. Jazz Pharmaceuticals is now managing the transition, keeping the domain alive for legacy stakeholders while redirecting to their corporate narrative. This is how mid-cap pharma digests acquisitions—not by shutting down domains, but by absorbing them into a larger commercial machine.